We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Compounder Draws Warning Letter for Misbranded, Unapproved Drugs
Compounder Draws Warning Letter for Misbranded, Unapproved Drugs
The FDA Philadelphia district office has issued a warning letter to a compounding pharmacy in Allentown, PA over misbranded drugs and sterility issues.